• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发结局与概率的框架设定:乳腺癌患者在假设患者情境中对辅助化疗(ACT)的选择

Framing of outcome and probability of recurrence: breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios.

作者信息

Zimmermann C, Baldo C, Molino A

机构信息

Dipartimento di Medicina e Sanità Pubblica, Servizio di Psicologia Medica, Università di Verona, Italy.

出版信息

Breast Cancer Res Treat. 2000 Mar;60(1):9-14. doi: 10.1023/a:1006342316373.

DOI:10.1023/a:1006342316373
PMID:10845804
Abstract

PURPOSE

To examine the effects of framing of outcome and probabilities of cancer occurrence on the treatment preference which breast cancer patients indicate for hypothetical patient scenarios.

METHODS

A modified version of the Decision Board Instrument (Levine et al. 1992) was administered to 35 breast cancer patients with past ACT experience. Patients expressed their choice regarding ACT for six scenarios which were characterized by either negative or positive framing of outcome and by one of the three levels of probability of recurrence (high, medium, low).

RESULTS

The framing had no influence on ACT choices over all three probability levels. The majority chose ACT for high and medium risk and one third switched from ACT to No ACT in the low-risk condition. This switch was statistically significant.

CONCLUSION

Hypothetical treatment decisions against ACT occur only when the probability of recurrence is low and the benefit of ACT is small. This finding for patients with past experience of ACT is similar to those reported for other oncological patient groups still in treatment.

摘要

目的

探讨结果的呈现方式以及癌症发生概率对乳腺癌患者针对假设患者情景所表明的治疗偏好的影响。

方法

对35名有过辅助化疗(ACT)经历的乳腺癌患者使用了决策板工具(Levine等人,1992年)的修改版。患者对六种情景表达了他们对辅助化疗的选择,这些情景的特征是结果呈现为消极或积极,以及复发概率的三个水平之一(高、中、低)。

结果

在所有三个概率水平上,呈现方式对辅助化疗的选择没有影响。大多数人在高风险和中等风险时选择辅助化疗,在低风险情况下,三分之一的人从辅助化疗转向不进行辅助化疗。这种转变具有统计学意义。

结论

只有当复发概率低且辅助化疗的益处小时,才会出现反对辅助化疗的假设治疗决策。这一针对有辅助化疗经历患者的发现与仍在接受治疗的其他肿瘤患者群体的报告结果相似。

相似文献

1
Framing of outcome and probability of recurrence: breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios.复发结局与概率的框架设定:乳腺癌患者在假设患者情境中对辅助化疗(ACT)的选择
Breast Cancer Res Treat. 2000 Mar;60(1):9-14. doi: 10.1023/a:1006342316373.
2
A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer.一种用于引出患者对乳腺癌辅助化疗偏好的床边决策工具。
Ann Intern Med. 1992 Jul 1;117(1):53-8. doi: 10.7326/0003-4819-117-1-53.
3
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.帮助患者做出明智选择:一项关于淋巴结阴性乳腺癌辅助化疗决策辅助工具的随机试验
J Natl Cancer Inst. 2003 Apr 16;95(8):581-7. doi: 10.1093/jnci/95.8.581.
4
Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.基于 EndoPredict 检测结果增强早期乳腺癌辅助化疗决策
Psychooncology. 2018 Apr;27(4):1264-1269. doi: 10.1002/pon.4664. Epub 2018 Mar 25.
5
A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.早期乳腺癌中青年患者与老年患者对辅助化疗和激素治疗偏好的前瞻性比较
Clin Breast Cancer. 2016 Oct;16(5):379-388. doi: 10.1016/j.clbc.2016.04.001. Epub 2016 Apr 21.
6
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.安大略省前瞻性评估 21 基因复发评分检测在乳腺癌决策中的应用。
J Clin Oncol. 2016 Apr 1;34(10):1065-71. doi: 10.1200/JCO.2015.62.8503. Epub 2015 Nov 23.
7
Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.乳腺癌辅助化疗:复发风险的呈现方式如何影响决策制定。
J Clin Oncol. 2003 Dec 1;21(23):4299-305. doi: 10.1200/JCO.2003.06.025. Epub 2003 Oct 27.
8
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.采用 21 基因检测指导早期乳腺癌辅助化疗决策:德国环境下的成本效益评估。
J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.
9
Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?早期乳腺癌患者辅助化疗疗效与心脏毒性之间的权衡:相互竞争的风险重要吗?
Breast J. 2017 Jul;23(4):401-409. doi: 10.1111/tbj.12757. Epub 2017 Jan 24.
10
When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.当基因组检测结果与标准检测结果出现差异时:对乳腺癌患者化疗偏好的影响
Breast Cancer Res Treat. 2009 Sep;117(1):25-9. doi: 10.1007/s10549-008-0175-2. Epub 2008 Sep 11.

引用本文的文献

1
Positive Attribute Framing Increases COVID-19 Booster Vaccine Intention for Unfamiliar Vaccines.积极属性框架效应会增加对不熟悉疫苗的新冠加强针接种意愿。
Vaccines (Basel). 2022 Jun 16;10(6):962. doi: 10.3390/vaccines10060962.
2
Survival benefit needed to undergo chemotherapy: Patient and physician preferences.接受化疗所需的生存获益:患者及医生的偏好
Cancer. 2017 Aug 1;123(15):2821-2828. doi: 10.1002/cncr.30671. Epub 2017 Mar 21.
3
Effect of endurance for adverse drug reactions on the preference for aggressive treatments in cancer patients.
癌症患者药物不良反应耐受性对积极治疗偏好的影响。
Support Care Cancer. 2015 Apr;23(4):1091-7. doi: 10.1007/s00520-014-2439-1. Epub 2014 Oct 8.
4
Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study.非转移性乳腺癌患者辅助治疗决策的人际影响和态度:BQUAL 研究中按年龄和种族/族裔划分的差异考察。
Breast Cancer Res Treat. 2013 Feb;137(3):817-28. doi: 10.1007/s10549-012-2370-4. Epub 2012 Dec 22.
5
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.美国保险计划在早期乳腺癌多基因检测方面的经验。
J Oncol Pract. 2011 May;7(3 Suppl):e38s-45s. doi: 10.1200/JOP.2011.000303.
6
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.老年女性乳腺癌辅助化疗决策:患者偏好的作用及其与医生的相互作用。
J Clin Oncol. 2010 Jul 1;28(19):3146-53. doi: 10.1200/JCO.2009.24.3295. Epub 2010 Jun 1.
7
Describing treatment effects to patients.向患者描述治疗效果。
J Gen Intern Med. 2003 Nov;18(11):948-59. doi: 10.1046/j.1525-1497.2003.20928.x.